Myocyte-Specific Upregulation of ACE2 in Cardiovascular Disease: Implications for SARS-CoV-2-Mediated Myocarditis
- PMID: 32795091
- PMCID: PMC7424896
- DOI: 10.1161/CIRCULATIONAHA.120.047911
Myocyte-Specific Upregulation of ACE2 in Cardiovascular Disease: Implications for SARS-CoV-2-Mediated Myocarditis
Abstract
Supplemental Digital Content is available in the text.
Keywords: COVID-19; cardiovascular diseases; heart; myocarditis; severe acute respiratory syndrome coronavirus 2.
Conflict of interest statement
Drs Papangeli, Akkad, Hayat, and Stegmann are employees of Bayer US LLC (a subsidiary of Bayer AG) and may own stock in Bayer AG. Dr Ellinor is supported by a grant from Bayer AG to the Broad Institute focused on the genetics and therapeutics of cardiovascular diseases. Dr Ellinor has also served on advisory boards or consulted for Bayer AG, Quest Diagnostics, MyoKardia, and Novartis. Dr Margulies has research grant funding from Sanofi-Aventis and has also served on advisory boards for MyoKardia and Pfizer. The other authors report no conflicts.
Figures
Update of
-
Myocyte Specific Upregulation of ACE2 in Cardiovascular Disease: Implications for SARS-CoV-2 mediated myocarditis.medRxiv [Preprint]. 2020 Apr 14:2020.04.09.20059204. doi: 10.1101/2020.04.09.20059204. medRxiv. 2020. Update in: Circulation. 2020 Aug 18;142(7):708-710. doi: 10.1161/CIRCULATIONAHA.120.047911. PMID: 32511660 Free PMC article. Updated. Preprint.
References
-
- Tucker NR, Chaffin M, Fleming SJ, Hall AW, Parsons VA, Bedi KC, Jr, Akkad A-D, Herndon CN, Arduini A, Papangeli I, et al. Transcriptional and cellular diversity of the human heart [published online May 14, 2020]. Circulation. doi: 10.1161/circulationaha.119.045401. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.045401. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
